Jodi Andrews

Jodi Andrews

Offline Online

Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

320 0 Hodgkin Lymphoma
Play
Want to watch this again later?
Sign in to add this video to a playlist. Login

Date added (newest)

61706a46b1e72

61706a46b1e72

Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

Tailoring Therapy to Older Patients with Acute Myeloid Leukemia

Tailoring Therapy to Older Patients with Acute Myeloid Leukemia

Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

61706a46b1e72

15 0 Acute Lymphoblastic Leukemia



Want to watch this again later?
Sign in to add this video to a playlist. Login

Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

320 0 Hodgkin Lymphoma

The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy, avoid unnecessary treatment and associated toxicity, and optimize outcomes for patients with Hodgkin lymphoma (HL). In this activity, participants will learn about the different PET-adapted strategies being investigated in HL, with a focus on the interpretation of data for the practical use of interim PET, to help providers evaluate the current clinical evidence and applicability to their practice.

Want to watch this again later?
Sign in to add this video to a playlist. Login

Tailoring Therapy to Older Patients with Acute Myeloid Leukemia

217 0 Acute Lymphoblastic Leukemia

Presented by Aziz Nazha, MD. Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60% of newly diagnosed AML patients being 60 or older. Older patients pose unique therapeutic challenges that have been largely unmet to date. This activity will review and discuss decision-making strategies outlining when and how to treat this patient population in your practice. In addition, Dr. Nazha will provide an overview of the current treatment paradigms available, as well as agents currently approved or under investigation which may have a potential role in the outcome of the older patient with AML. CE credit available at www.managingAML.com (expires 9/14/18).

Want to watch this again later?
Sign in to add this video to a playlist. Login

Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

187 0 Acute Lymphoblastic Leukemia

Presented by Ehab Atallah, MD. There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic chemotherapy, especially for a generally older patient population. Hypomethylating agents (HMAs) have demonstrated a benefit in patients with AML, especially those who require less aggressive therapy, but there is a need for improved efficacy and survival outcomes. In this activity, participants will learn about HMAs in existing treatment paradigms, as well as the investigational landscape of novel therapies in combination with HMAs, and their potential impact on treatment outcomes for patients with AML. CE credit available at www.managingAML.com (expires 10/30/18).

Want to watch this again later?
Sign in to add this video to a playlist. Login
My videos
61706a46b1e72

61706a46b1e72


15 Views
1 year Ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
Practical Application of PET-Adapted Therapy in Hodgkin L...
320 Views
4 years Ago
Jodi Andrews
Want to watch this again later?
Sign in to add this video to a playlist. Login
Tailoring Therapy to Older Patients with Acute Myeloid Leukemia
Tailoring Therapy to Older Patients with Acute Myeloid Le...
217 Views
5 years Ago
Jodi Andrews
Want to watch this again later?
Sign in to add this video to a playlist. Login
Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents
Novel Treatment Combinations in Development for AML: The ...
187 Views
5 years Ago
Jodi Andrews
Want to watch this again later?
Sign in to add this video to a playlist. Login
Loading